Form 4: Aura Biosciences CEO Sells Shares for Tax Obligations

Aura Biosciences' President and CEO, Elisabet de los Pinos, sold 16,928 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Elisabet de los Pinos, President and Chief Executive Officer of Aura Biosciences, Inc. (AURA), reported a sale of common stock.
• The transaction occurred on January 20, 2026.
• A total of 16,928 shares of common stock were disposed of.
• The shares were sold at a weighted average price of $4.86, with individual transaction prices ranging from $4.73 to $4.86.
• The sale was automatic and non-discretionary, executed solely to cover tax withholding obligations in connection with the vesting of restricted stock units.
• Following the transaction, de los Pinos directly owns 457,463 shares and indirectly owns 127,763 shares through the Elisabet de los Pinos Revocable Trust.

Sentiment

Score: 5

Explanation: The transaction is a routine, non-discretionary sale to cover tax obligations from RSU vesting, which is a neutral event and does not reflect positively or negatively on the company's performance or outlook.

Future Outlook

N/A. This filing is a report of an insider transaction and does not contain forward-looking statements or guidance regarding the company's future performance.

Management Comments

• The sales reported represent the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units.
• Such sales were automatic and not at the discretion of the Reporting Person.

Industry Context

N/A. This Form 4 filing details a routine insider transaction for tax purposes and does not provide information relevant to broader industry trends or competitive analysis.

Related Party Transactions

• Elisabet de los Pinos indirectly holds 127,763 shares through the Elisabet de los Pinos Revocable Trust U/D/T dated April 8, 2016, of which she is a trustee.

Stakeholder Impact

• Shareholders: Minimal impact as the sale is a routine, non-discretionary transaction for tax purposes and does not signal a change in management's confidence or company fundamentals.

Next Steps

• The Reporting Person undertakes to provide full information regarding the number of shares sold at each separate price within the reported range upon request to the Issuer, any security holder, or the SEC staff.

Key Dates

Keywords

Aura Biosciences, AURA, Elisabet de los Pinos, Insider Trading, Form 4, Stock Sale, Restricted Stock Units, Tax Withholding